Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus GEMOX as first-line therapy for advanced biliary tract tumors
ChiCTR2600117154Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in biliary cancer, gallbladder cancer, intrahepatic cholangiocarcinoma (ICC) and 1 more, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Jan 2026; status: completed.
02
Drugs
toripalimab
03
Conditions
biliary cancergallbladder cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2600117154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117154.